pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Biotech executive Steven Quay dropped from consideration for NIAID director role

Oct 9, 2026·read at STAT ↗Neutral

Steven Quay, a biotech executive known for promoting the lab‑leak theory, was reportedly in the running to lead the National Institute for Allergy and Infectious Diseases.

A source familiar with the selection process said Quay is no longer the leading candidate and is expected to take on a consulting role rather than the directorship.

The White House and the Department of Health and Human Services have not responded to requests for comment, and the decision highlights concerns about his lack of infectious‑disease experience.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Biotech leader, leading lab leak theorist no longer in consideration for top infectious disease role”

read at STAT ↗
531 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING4National Institutes of Health
topics
Infectious Disease3

related stories

  • Jul 29Opinion: The VA could help America win the biotechnology race with ChinaSTAT
  • Jul 28STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDSTAT
  • Jun 11Opinion: How long Covid’s scientific stalemate made it politically erasableSTAT
  • Jun 6Opinion: I led the U.S. CDC response to the 2014 Ebola epidemic. The new outbreak needs massive, immediate, meticulous actionSTAT
  • Apr 30Opinion: Congress must hold RFK Jr. accountable after hearingsSTAT